氯沙坦治疗高血压合并高尿酸血症疗效的临床观察被引量：2

Effects of treating uricacidemia by losartan in patients with hypertension associated hyperuricemia

下载PDF

导出

摘要目的 :研究氯沙坦在治疗高血压合并高尿酸血症时的作用。方法 :选择高血压合并高尿酸血症患者10 0例 ,随机分两组 ,各 5 0例 ,1组单用氯沙坦 ,2组为氯沙坦联用氢氯噻嗪等其他降血压药物者 ;并以卡托普利治疗为对照组 ,观察治疗后 3天、1周、2周、4周各组患者血尿酸、尿尿酸、尿蛋白的水平变化。结果 :氯沙坦治疗 1周后血尿酸明显下降 ,2 4h尿尿酸排出量明显增加 ,同时伴 2 4h尿蛋白排出减少。结论 :氯沙坦降压同进能降血尿酸 ,且对肾脏有保护作用。 Objective: To study the effects of by losartan in treating patients with hypertension associated with hyperuricemia.Methods: 96 patients with hypertension and were divided into two groups by random (group 1∶50cases, group2∶46cases). Group 1 included patients only taking.Group 2 included patients taking losartan combined other antihypertensive drugs including hydrochlorothiazide. 40cases patients taking captopril was control group. Observed the change of uricacidemia, uricacid in urine and urinary protein of two groups after treatment for 3 days, 1 week, 2 weeks and 4 weeks.Results: Uricacidemia had apparently reduced after losartan treatment for 3 days and the outage of 24 h uricacid had apparently increased with the outage of 24 h urnary protein decreasing.Conclusion: Losartan can be used for underpressure and treating uricacidemia and protection of kidneys.

作者孙宏方

机构地区河南省平顶山市第一人民医院心内科

出处《河南医学研究》 CAS 2004年第4期329-331,共3页 Henan Medical Research

关键词治疗氯沙坦高血压高尿酸血症血尿酸尿蛋白患者排出量选择合并 losartan hypertension uric acid

分类号 R544 [医药卫生—心血管疾病] R735.7 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1Nakashima M,Uematsu T,Kosuge K,et al.Pilot if the uricosuric effect of Dup-753,a new angiotensin Ⅱ receptor antagonist,in healthy subjects[J].Eur J Clin Pharmacol,1992,42(5):333-335.
2Mallion JM, Bradstreet DC, Makris L, et al.Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension[J].J Hypertens, 1995,13(suppll):35-41.
3Roca-Cusachs A,Perico N,Amuchastegui CS, et al. A randomized,Double-bilnd compari-son of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate seeential hypertension[J].Acta Cardiologica, 1997,52(6):495-506.
4Goldberg AI,Dunlay MC,Sweet CS,et al. Salty and torlerability of losartan potassium, an angiotensin Ⅱ receptor antagonist,compared with by-drochlorthiazide.atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension[J].AMJ Cardiol,1995,75(4):793-795.
5Capozide.In:Physicians DeskReference.48thed. Mont-vale,NJ:Medical Economics Data Production Company,1995.714-717.
6Edwards RM,Triza W, Stack EJ,lnteraction of nonpeptide angiotension Ⅱ recepor antgonists with the urate transports in rat renal brush-border membranes[J].Journal of Pharmacology and Experimental Therapeutics, 1996,276(1):125-129.